LONDON (Reuters) - Britain's healthcare costs watchdog has given its backing to eye drug Lucentis after Swiss drugmaker Novartis offered it at a discount to the country's National Health Service. The National Institute for Health and Clinical Excellence, in a reversal of an earlier decision, said on Friday Lucentis should now be available for patients with diabetic macular oedema (DMO) which can cause sight loss in people with diabetes. In November 2011, NICE said it could not recommend the drug, known generically as ranibizumab, as an effective use of NHS resources. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment